• Explore /
  • Poster
  • / Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.

Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.

Abstract Poster

Authors

null

Pooja Karukonda

Duke Cancer Institute, Durham, NC

Pooja Karukonda , Brian G. Czito , Eileen Duffy , Hope Elizabeth Uronis , Thomas A. D'Amico , John H Strickler , Donna Niedzwiecki , Christopher Willett , Manisha Palta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT03064490

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4062)

DOI

10.1200/JCO.2023.41.16_suppl.4062

Abstract #

4062

Poster Bd #

383

Abstract Disclosures

Similar Posters

First Author: Pooja Karukonda

First Author: Jianwei Zhang

First Author: David B. Page

First Author: Sara P. Myers